Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IVF hartmann Holding AGXSWX:VBSN 72 Debt-to-EBITDA is 0.05 as of Dec. 2025, which is at its 10-year median of 0.05. GuruFocus rates XSWX:VBSN with a GF Score™ of 72/100 and a GF Value™ of CHF143.40 (Modestly Undervalued). Among 468 Medical Devices & Instruments companies, IVF hartmann Holding AG ranks better than 95.09% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for IVF hartmann Holding AG's Debt-to-EBITDA or its related term are showing as below:
XSWX:VBSN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04 Med: 0.05 Max: 0.07
Current: 0.05
During the past 13 years, the highest Debt-to-EBITDA Ratio of IVF hartmann Holding AG was 0.07. The lowest was 0.04. And the median was 0.05.
XSWX:VBSN's Debt-to-EBITDA is ranked better than 95.09% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs XSWX:VBSN: 0.05
IVF hartmann Holding AG (XSWX:VBSN) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IVF hartmann Holding AG Debt-to-EBITDA Related Terms
IVF hartmann Holding AG Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:VBSN vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, IVF hartmann Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IVF hartmann Holding AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, IVF hartmann Holding AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IVF hartmann Holding AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
IVF hartmann Holding AG (XSWX:VBSN) has a Debt-to-EBITDA of 0.05 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IVF hartmann Holding AG. This is near median its historical median of 0.05. Over the past decade, IVF hartmann Holding AG's Debt-to-EBITDA has ranged from 0.04 to 0.07. According to the industry distribution chart, IVF hartmann Holding AG ranks #23 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 4.9%.
Is IVF hartmann Holding AG's Debt-to-EBITDA too high?
IVF hartmann Holding AG's current Debt-to-EBITDA of 0.05 is near median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.07. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. IVF hartmann Holding AG's value of 0.05 is 96.8% below this industry median. Based on the distribution chart, IVF hartmann Holding AG ranks #23 out of 468 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, IVF hartmann Holding AG has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IVF hartmann Holding AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, IVF hartmann Holding AG ranks #23 out of 468 companies for Debt-to-EBITDA. This places IVF hartmann Holding AG in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.59. IVF hartmann Holding AG's value of 0.05 is 96.8% below this benchmark. Historically, IVF hartmann Holding AG's own Debt-to-EBITDA has ranged from 0.04 to 0.07 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 1.59, IVF hartmann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IVF hartmann Holding AG's current Debt-to-EBITDA of 0.05 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IVF hartmann Holding AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IVF hartmann Holding AG's current Debt-to-EBITDA is 0.05, which is near median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IVF hartmann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, IVF hartmann Holding AG (XSWX:VBSN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF143.40, compared to a current price of CHF124.00 — trading 13.5% below its estimated fair value. The current Debt-to-EBITDA is 0.05, which is near median its 10-year median of 0.05 and 96.8% below the Medical Devices & Instruments industry median of 1.59. IVF hartmann Holding AG's overall GF Score™ is 72/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For IVF hartmann Holding AG (XSWX:VBSN), the current Debt-to-EBITDA is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IVF hartmann Holding AG (XSWX:VBSN) Overvalued in 2026?
Based on GuruFocus' analysis, IVF hartmann Holding AG stock appears to be undervalued.
The current stock price of CHF124.00 is trading 13.5% below its estimated GF Value™ of CHF143.40.
GuruFocus considers IVF hartmann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:VBSN:
Debt-to-EBITDA: 0.05 (near median its 10-year median of 0.05)
GF Value™: CHF143.40 vs. price of CHF124.00 (13.5% below fair value)
Industry Position: 96.8% below the Medical Devices & Instruments median (#23 of 468)
No single metric tells the full story. See the XSWX:VBSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IVF hartmann Holding AG engages in production and supply of medical, pharmaceutical and hygiene products in Switzerland, it offers products such as surgical disposable, disposable dental, first aid, therapeutic plaster, cotton wool, wound care among others. The company operates in four segment wound care, incontinence management, infection management and Other group activities.
72GF Score
Get the complete analysis for XSWX:VBSN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VBSN has been successfully added to your 
